|
| 36315007 | Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. | Blood Adv | 2023 |
| 37590099 | Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement. | Leuk Lymphoma | 2023 |
| 37572683 | Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. | Lancet Haematol | 2023 |
| 37078412 | Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. | Cancer | 2023 |
| 37379495 | Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. | J Clin Oncol | 2023 |
| 37467065 | Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations. | JNCI Cancer Spectr | 2023 |
| 34932793 | Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. | Blood Adv | 2022 |
| 35443022 | Transplant outcomes after CPX-351 vs 7â¿¿+â¿¿3 in older adults with newly diagnosed high-risk and/or secondary AML. | Blood Adv | 2022 |
| 35667128 | Central nervous system involvement in adult acute myeloid leukemia patients. | Leuk Res | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 36289532 | Efficacy and safety of CPX-351 versus 7â¿¿+â¿¿3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. | J Hematol Oncol | 2022 |
| 35042970 | Functional characterization of NPM1-TYK2 fusion oncogene. | NPJ Precis Oncol | 2022 |
| 35096610 | <i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. | Front Oncol | 2022 |
| 35095270 | Accelerating Cancer Patient Recruitment Through a Mobile Application (Clinical Trial Finder). | Cancer Inform | 2022 |
| 35142581 | Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. | Leuk Lymphoma | 2022 |
| 32812335 | High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome. | Int J Lab Hematol | 2021 |
| 33514657 | Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. | Mol Cancer Res | 2021 |
| 33593202 | The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia. | Expert Rev Hematol | 2021 |
| 33724305 | Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. | Blood Adv | 2021 |
| 34439266 | A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. | Cancers (Basel) | 2021 |
| 34718324 | A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. | Blood Cancer J | 2021 |
| 34771451 | Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. | Cancers (Basel) | 2021 |
| 34171279 | CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. | Lancet Haematol | 2021 |
| 34256819 | Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7â¿¿+â¿¿3 in older adults with newly diagnosed high-risk/secondary AML. | J Hematol Oncol | 2021 |
| 32432489 | Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. | Leuk Lymphoma | 2020 |
| 33106665 | Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. | Nat Med | 2020 |
| 32998961 | A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. | Clin Cancer Res | 2020 |
| 32820015 | Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <i>HOXA9</i> and <i>MEIS1</i> Expression. | Clin Cancer Res | 2020 |
| 32590108 | Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. | Leuk Res | 2020 |
| 32313104 | Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells. | Nat Cell Biol | 2020 |
| 30382305 | Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment. | Ann Hematol | 2019 |
| 31888052 | A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. | Cancers (Basel) | 2019 |
| 30203489 | Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. | Br J Haematol | 2019 |
| 31098682 | A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. | Cancer Chemother Pharmacol | 2019 |
| 30892988 | Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. | J Clin Oncol | 2019 |
| 31170519 | Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. | Biol Blood Marrow Transplant | 2019 |
| 30543769 | Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. | Hematol Oncol Stem Cell Ther | 2019 |
| 29339629 | Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. | Acta Haematol | 2018 |
| 30130689 | A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics. | Leuk Res | 2018 |
| 30024784 | CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. | J Clin Oncol | 2018 |
| 29928848 | Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. | Hematol Oncol Stem Cell Ther | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 29278676 | Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. | Hematol Oncol Stem Cell Ther | 2018 |
| 28603071 | Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation. | Biol Blood Marrow Transplant | 2017 |
| 25471252 | Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. | J Oncol Pharm Pract | 2016 |
| 27760758 | Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation. | Blood | 2016 |
| 26939585 | A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant. | J Clin Apher | 2016 |
| 27013276 | Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy. | Hematol Oncol Stem Cell Ther | 2016 |
| 27111048 | Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. | Bone Marrow Transplant | 2016 |
| 26031713 | Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. | J Clin Apher | 2016 |